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Neurokinin-1 receptor blocking has been shown to be beneﬁcial against lung injury in polymicrobial sepsis. In this paper, we
evaluated the possible mediators and the mechanism involved. Mice were subjected to cecal ligation and puncture (CLP-) induced
sepsis or sham surgery. Vehicle or SR140333 [1mg/kg; subcutaneous (s.c.)] was administered to septic mice either 30min before
or 1 h after the surgery. Lung tissue was collected 8h after surgery and further analyzed. CLP alone caused a signiﬁcant increase
in the activation of the transcription factors, protein kinase C-α, extracellular signal regulated kinases, neurokinin receptors, and
substancePlevelsinlungwhencomparedtosham-operatedmice.SR140333injectedpre-andpostsurgerysigniﬁcantlyattenuated
theactivationoftranscriptionfactorsandproteinkinaseC-αand theplasmalevels ofsubstancePcompared toCLP-operated mice
injected with the vehicle. In addition, GR159897 (0.12mg/kg; s.c.), a neurokinin-2 receptor antagonist, failed to show beneﬁcial
eﬀects. We conclude that substance P acting via neurokinin-1 receptor in sepsis initiated signaling cascade mediated mainly by
protein kinase C-α,l e dt oN F - κB and activator protein-1 activation, and further modulated proinﬂammatory mediators.
1.Introduction
Sepsis is an intense systemic inﬂammatory response syn-
drome (SIRS) generally caused by bacterial infection [1].
Substance P (SP), a preprotachykinin-A (PPTA)g e n ep r o d -
uct, is an immunoregulatory neuropeptide implicated in
various inﬂammatory diseases including sepsis. We have
previously shown that PPTA gene knock-out mice are
protected signiﬁcantly against polymicrobial sepsis [2], and
neurokinin-1 receptor (NK-1R) antagonist treatment was
beneﬁcial against lung injury in mouse sepsis model [3]. The
mechanism by which NK-1R blocking protects against lung
injury was yet to be elucidated.
The NF-κB transcription factor system is known to
control the expression of a number of genes involved in
the innate immune response of the body against infection
and inﬂammation. Genes responsible for immunoreceptors,
cytokines, chemokines, and apoptosis are all modulated by
this important family of transcription factors [4]. NF-κB
activity is reported to be impaired in chronic inﬂammation
[5], and inhibition of NF-κBh a sb e e ns u g g e s t e dt ob e
beneﬁcial in maintaining the balance between pro- and anti-
inﬂammatory cytokines [6]. Activator Protein-1 (AP-1) is
another transcription factor that is induced by inﬂammatory
cytokines and cellular stress. Phosphorylation of AP-1 is
necessary for transcriptional activity.
Phosphorylation of NF-κB and AP-1 and thus tran-
scription of proinﬂammatory mediators are facilitated by
the activation of various mitogen-activated protein kinases
(MAPKs). MAPKs in turn are activated by bacterial prod-
ucts, cytokines, and chemokines [7, 8]. AP-1 c-Jun is
reported to be phosphorylated in vitro by extracellular
signal-regulated kinases (ERK1 and ERK2) [9, 10]. ERK
is also shown to be a regulator of NF-κBa c t i v i t y[ 11].
ERK1/2 reportedly induce NF-κB activation by stimulating
downstream MAPK-activated protein kinases [12, 13]. p38
MAPKs are also activated by inﬂammatory cytokines and
environmental stress.
We explored the possible downstream mediators and
transcription factors involved in NK-1R antagonism in2 International Journal of Inﬂammation
sepsis. Apartfromanalyzingthe activationofNF-κB and AP-
1,proteinlevelsofMAPKs,proteinkinaseC(PKC)isoforms,
mRNA levels of NK-1R, neurokinin-2 receptor (NK-2R),
and SP concentrations were also evaluated. Although the
eﬀects of SP were found to be mediated mainly via NK-
1R in sepsis, it was interesting to explore if NK-2R had any
role in the actions of SP in sepsis. Thus, we also studied the
eﬀect of blocking NK-2R with GR159897, a highly potent,
selective, and long-acting nonpeptide NK-2R antagonist, in
polymicrobial sepsis. Lung myeloperoxidase (MPO) activity,
chemokine, and cytokine levels were measured to evaluate
the beneﬁcial eﬀects, if any, of NK-2R antagonism in sepsis.
2.MaterialsandMethods
2.1. Animal Ethics. All animal experiments performed were
in accordance with the guidelines of the DSO Animal Care
and Use Committee (DSOACUC), Singapore, which follows
the established International Guiding Principles for Animal
Research. Mice were maintained at a controlled temperature
(21–24
◦C) and lighting (12 hours light/dark cycles) and fed
with standard laboratory chow and drinking water, provided
ad libitum.
2.2. Induction of Polymicrobial Sepsis. Swiss mice (male,
25–30g) used for the study were randomly assigned to
sham or cecal ligation and puncture (CLP) experimental
groups (n>6 in each group). Polymicrobial sepsis
was induced in mice by CLP as described earlier [14–
17]. The same surgical procedure except cecal ligation and
puncture was performed on sham-operated animals. Vehicle
(DMSO diluted in PBS, 0.25% v/v) or SR140333 [1mg/kg;
0.25mg/mL, subcutaneous (s.c.)] was administered to CLP-
operated mice either 30 minutes before (pretreatment) or 1
hour after (posttreatment) the CLP.
Another identical set of mice were subjected to either
sham or CLP surgery as above, and the CLP group of
mice were injected with vehicle (DMSO diluted in PBS,
0.25% v/v) or GR159897 (Tocris Bioscience, Missouri, USA)
(0.12mg/kg; 0.25mg/mL, s.c.) 1 hour after CLP. GR159897
is reported to be highly potent and speciﬁc in antagonizing
NK-2R with aﬃnity in subnanomolar range [18]. GR159897
(0.12mg/kg;i.v.)hasbeenshowntoantagonizebronchocon-
striction induced by NK-2R agonist (28 times) in guinea-
pig and also negligibly aﬀect NK-1R and NK-3R [19]. Thus,
we chose a small dose (0.12mg/kg, s.c.) of GR159897 to be
suﬃcient to block NK-2R.
The animals were sacriﬁced 8 hours after surgery by an
i.p. injection of a lethal dose of pentobarbitone (Jurox Pty
Ltd, Rutherford, NSW, Australia). Blood was collected by
cardiac puncture, heparinized, and centrifuged, and plasma
wasremovedandstoredat−80
◦C.Samplesoflungweresnap
frozen in liquid nitrogen and stored at −80
◦Cf o rs u b s e q u e n t
measurement.
2.3. Preparation of Nuclear Extract. Nuclear extracts were
prepared from lung tissue using Active Motif nuclear extrac-
tion kit (Carlsbad, CA, USA) following the instructions
from the manufacturer. Brieﬂy, lung tissue (50mg) was
homogenized in hypotonic buﬀer containing detergent,
incubated for 15 minutes on ice, and then centrifuged at
850g, 4◦C for 10 minutes. The pellets were resuspended in
hypotonic buﬀer, treated with detergent, and centrifuged at
14,000g, 4◦C for 30seconds. The nuclei in the pellets were
lysed with complete lysis buﬀer and the nuclear proteins
solubilized in the buﬀer containing protease inhibitors. The
nuclear fraction was separated by centrifuging at 14,000g,
4◦C for 10 minutes and collecting the supernatant. Protein
concentrationinthenuclearextractwasdeterminedbyusing
Bradford protein assay kit (Bio-Rad Laboratories, CA, USA).
Protein concentration was calculated using a standard curve.
2.4. NF-κB DNA-Binding Activity. ELISA-based TransAM
NF-κB p65 transcription factor assay kit (Active Motif,
Carlsbad, CA, USA) was used to measure NF-κB binding to
DNA and activation, as per the manufacturer’s instruction.
Nuclear proteins (5μg) from the nuclear extract were added
to each well coated with an unlabeled oligonucleotide
containing the consensus binding site for NF-κB( 5  -
GGGACTTTCC-3 )[ 20] and incubated for 1 hour at room
temperature to allow the active form of NF-κB to bind.
A primary antibody directed against activated NF-κBp 6 5
subunit was added to detect the NF-κBc o m p l e xb o u n dt o
theoligonucleotide.Additionofasecondaryantibodyconju-
gated to horseradish peroxidase (HRP) provided a sensitive
colorimetric estimation by spectrophotometry. Absorbance
was measured at 450nm using microplate reader (Tecan
Systems Inc., San Jose, CA, USA).
2.5. AP-1 DNA-Binding Activity. TransAM AP-1 c-Jun tran-
scription factor assay kits (Active Motif, Carlsbad, CA, USA)
were used to detect and quantify AP-1 activation. AP-1
dimers in the nuclear extract (5μg of protein) were added
to the 96-well microplate with immobilized oligonucleotide
that had a 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-
responsive element (TRE) (5 -TGA(C/G)TCA-3 )t os p e c i ﬁ -
cally bind to the oligonucleotide. Primary antibody was used
to recognize accessible epitopes on c-Jun proteins upon DNA
binding. Secondary antibody conjugated to HRP was added
forthecolorimetricreaction.Absorbancewasreadat450nm
using microplate reader (Tecan Systems Inc., San Jose, CA,
USA).
2.6. Western Blot Experiment. Protein levels of IκBα,P K C α,
PKCδ,P K C ε, and MAPKs in lung homogenates were ana-
lyzedbyWesternblot.80μgofthelungproteinwasseparated
ona12%SDS-polyacrylamidegel(Invitrogen,Carlsbad,CA,
USA) and transferred to PVDF membranes (Millipore, MA,
USA)byelectrophoresis.Nonspeciﬁcbindingwasblockedby
incubatingthemembraneatroomtemperaturein5%nonfat
dry milk in phosphate-buﬀered saline Tween 20 (PBST)
(0.05% Tween 20 in phosphate-buﬀered saline) for 1 hour.
The blots were incubated overnight at 4◦Cw i t hp r i m a r y
antibody (Cell Signalling Technology) at 1:1000 dilutions
in 2.5% nonfat dry milk in PBST. The membranes were
then washed four times with PBST and incubated with goatInternational Journal of Inﬂammation 3
anti-rabbitHRP-conjugatedsecondaryantibody(SantaCruz
Biotechnology) at 1:2000 dilutions in 2.5% nonfat dry milk
in PBST for 2 hours. Visualization of the blot was done using
enhanced chemiluminescence (ECL) detection kit (Pierce,
Rockford, IL, USA) and with exposure to X-ray ﬁlms (CL-
XPosure, Pierce). Hypoxanthine guanine phosphoribosyl
transferase (HPRT) (Santa Cruz Biotechnology; 1:1000
dilution) was used as the housekeeping protein. The band
densities were quantiﬁed using a UVP bioimaging system
(UVP, Upland, CA, USA). The intensity of bands was
analyzedusingLabWorksImageAnalysissoftware(UVP,CA,
USA) and expressed as integrated optical density (IOD).
2.7. RNA Isolation and Quantiﬁcation. Total RNA was iso-
lated from the lung tissue (n>6 for each group) using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s protocol. RNeasy mini kit was used
to clean up the total RNA after extraction. Brieﬂy, extracted
RNA sample was lysed and homogenized in the presence of
ahighlydenaturingguanidine-thiocyanate-containingbuﬀer
to inactivate RNases leaving intact RNA. Ethanol was added
for appropriate binding, and the sample was applied to
an RNeasy Mini spin column to bind total RNA to the
membrane. Contaminants were washed away and high-
quality RNA was eluted in 30–100μL water. The quantity
of extracted RNA was determined by spectrophotometric
analysis (NanoDrop ND1000). RNA samples with A260/A280
ratioscloseto2.0(range:1.9–2.1)andintegritywereusedfor
reverse transcription-polymerase chain reaction (RT-PCR).
The integrity of RNA was assessed by 1% w/v denaturing
agarose gel electrophoresis using GelRed dye to stain 18S and
28S rRNA bands. The RNA sample was stored at −80
◦C until
RT-PCR.
2.8. Semiquantitative RT-PCR. Isolated lung RNA (1μg) was
reversely transcribed using iScript cDNA Synthesis Kit (Bio-
Rad, Hercules, CA, USA) at 25
◦Cf o r5m i n u t e s ,4 2
◦Cf o r
30 minutes, followed by 85
◦C for 5 minutes. The cDNA was
used as a template for PCR ampliﬁcation by iQ Supermix
(Bio-Rad, Hercules, CA, USA). The primer sequences and
optimalampliﬁcationconditionsforNK-1R,NK-2Rand18S
gene are given in Table 1. PCR ampliﬁcation was carried
out in MyCycler (Bio-Rad). The reaction mixture was ﬁrst
subjected to 95
◦C for 3–5 minutes, followed by an optimal
cycle of ampliﬁcation and a ﬁnal extension at 72
◦Cf o r
5–7 minutes. PCR products were analyzed on 1.5% w/v
agarose gel containing 0.1μL/mL GelRed and visualized
by the UVP bioimaging system (UVP, Upland, CA, USA).
The intensity of bands was analyzed using LabWorks Image
Analysis software (UVP). Densitometry results (IOD) from
PCR products were normalized to the mouse 18S band
densities.
2.9. Substance P Estimation. SP levels were measured in
lung and plasma using competitive ELISA kit (Bachem,
Peninsula Laboratories, USA) as per the manufacturer’s
protocol. Brieﬂy, the lung tissue was homogenized in 1mL
ice-cold SP assay buﬀer for 20seconds. The homogenate
was centrifuged (13000rpm, 20 minutes, 4◦C), and the
supernatant was separated. SP in the supernatant was
adsorbed on C18 separation column containing 200mg C18
(Bachem, Peninsula Laboratories, USA), as described in
[21]. The adsorbed peptide was then eluted with 1.5mL
of 75% v/v acetonitrile and freeze dried overnight. The
lyophilized sample was reconstituted in SP assay buﬀer, and
the absorbance was measured at 450nm. SP level was read
from a standard curve and expressed as nanograms per
milliliter for plasma and picograms per microgram of DNA
for lung (corrected for the DNA content of the tissue using
Hoechst dye 33256 [22]).
2.10. Myeloperoxidase (MPO) Activity and ELISA Analy-
sis. MPO activity, chemokine (CCL-2 and CXCL-2), and
cytokine (IL-6 and IL-1β) levels in lung were quantiﬁed as
described elsewhere [3]. Brieﬂy, tissue samples were homog-
enized in 20mM phosphate buﬀer (pH 7.4) and centrifuged
(10000 × g, 10 minutes, 4◦C), and the resulting pellet was
resuspendedin50mMphosphatebuﬀer(pH6.0)containing
0.5% hexadecyltrimethylammonium bromide (Sigma, St.
Louis, MO, USA). The suspension was subject to four cycles
of freezing and thawing and further disrupted by sonication
(40seconds). The sample was then centrifuged (10000 × g,5
minutes, 4◦C), and the supernatant was used for the MPO
assay. The reaction mixture consisted of the supernatant,
1.6mM tetramethylbenzidine (Sigma, St. Louis, MO, USA),
80mM sodium phosphate buﬀer (pH 5.4), and 0.3mM
hydrogen peroxide. This mixture was incubated at 37
◦Cf o r
110 seconds, the reaction was terminated with 2M H2SO4,
andtheabsorbancewasmeasuredat450nm.Theabsorbance
was then corrected for the DNA content of the tissue sample
[22].
For the ELISA analysis, anti-chemokine/cytokine pri-
mary antibody was coated onto 96-well ELISA plates and
incubated overnight at room temperature. Samples and
standards were added to the wells and incubated for 2 hours,
the wells were washed, and a biotinylated goat anti-mouse
chemokine/cytokine antibody was added for 2 hours. Plates
were washed again, and streptavidin conjugated to HRP was
added for 20 minutes. After a further wash, tetramethylben-
zidine was added for color development, and the reaction
was terminated with 2N H2SO4. Absorbance was measured
at 450nm. Sample concentration was estimated from the
standard curve. DNA assay was performed ﬂuorometrically
by using Hoechst dye 33256 [22]. The sample concentration
was then corrected for the DNA content of the tissue [22].
2.11. Statistical Analysis. A l lv a l u e sw e r ee x p r e s s e da sm e a n
± S.E.M. The signiﬁcance of changes was evaluated by using
ANOVA when comparing three or more groups and Tukey’s
method as a post hoc test for comparison among diﬀerent
groups. A P value of <.05 was considered to indicate a
signiﬁcant diﬀerence.
3. Results
3.1. Eﬀect of SR140333 Treatment on Lung NF-κBA c t i v a t i o n
after Sepsis. As NF-κB is an important transcription factor4 International Journal of Inﬂammation
Table 1: Primer sequences and optimal conditions used in PCR analysis.
Gene name Sense primer sequence (5 –3 ) Antisense primer sequence (5 –3 ) Ampliﬁcation conditions
No. of
ampliﬁcation
cycles
NK-1R CTT GCC TTT TGG AAC CGT GTG CAC TGT CCT CAT TCTCTT GTGGG 95
◦C3 0s ;5 9
◦C3 0s ;7 2
◦C3 0s 38
NK-2R TGC TGT CAT CTG GCT GGT AG TCT TCC TCG GTT GGT GTC CC 95
◦C3 0s ;6 1
◦C3 0s ;7 2
◦C3 0s 42
18S GTA ACC CGT TGA ACC CCA TT CCA TCC AAT CGG TAG TAG CG 95
◦C3 0s ;5 9
◦C3 0s ;7 2
◦C3 0s 24
involved in inﬂammatory diseases, activation and nuclear
translocation of NF-κB were measured after induction of
sepsis and treatment with the NK-1R antagonist. NF-κB
activity was signiﬁcantly increased (P<. 001) in vehicle-
treated (both pre- and posttreatment) mice 8 hours after
CLP compared to the sham group (Figure 1(a)). Injection
of SR140333, both 30 minutes before and 1 hour after
CLP, reduced the NF-κB activity signiﬁcantly (P<. 001)
(Figure 1(a)).
Western blot analysis was performed to evaluate the
activation and degradation of IκBα. When the inhibitory
protein IκBα is phosphorylated and degraded, NF-κBi s
freed for nuclear translocation. As expected, we observed a
signiﬁcant reduction in IκBl e v e l s( P<. 001) in vehicle-
treated (both pre- and posttreatment) mice 8 hours after
CLP compared to the sham group (Figure 1(b)). SR140333
treatment, both 30 minutes before and 1 hour after CLP,
restored the IκB levels signiﬁcantly (P<. 05) (Figure 1(b)).
3.2. Eﬀect of SR140333 Treatment on Lung AP-1 Activation
after Sepsis. Activation of another transcription factor that is
involvedinsepsis,AP-1c-Jun,wasalsomeasuredafterinduc-
tion of sepsis and treatment with the NK-1R antagonist. 8
hours after CLP, AP-1 activity was signiﬁcantly increased
(P<. 001) compared to the sham group in vehicle-treated
mice (Figure 2). S.c administration of the NK-1R antagonist,
SR140333, both 30 minutes before and 1 hour after CLP,
reduced the AP-1 activity signiﬁcantly (P<. 001).
3.3. Eﬀect of SR140333 Treatment on MAPKs and PKC
Isoforms in Sepsis. To evaluate the link between NK-1R
antagonist treatment and transcription factor inhibition,
western blot analysis was performed for various MAPKs:
ERK1/2, p38, and JNK. Signiﬁcant activation of ERK1/2
to the phosphorylated form was detected 8 hours after
CLP in vehicle-treated mice lung homogenates (Figure 3(a)).
SR140333 treatment, both 30 minutes before and 1 hour
after CLP, showed a trend to reduce the phospho ERK1/2
levels, although the reduction was not statistically signiﬁcant
(Figure 3(a)). p-p38 and p-JNK MAPKs showed very weak
signals and did not show signiﬁcant diﬀerences between the
groups (data not shown).
The enzyme PKC involved in signal transduction of G
protein-coupled receptors (GPCRs) was also evaluated in
sepsis. Signiﬁcant phosphorylation and activation of PKCα
was observed 8 hours after sepsis in mice injected with only
vehicle compared to the sham group (Figure 3(b)). Blocking
of NK-1R with SR140333 (both pre- and posttreatment)
resulted in a signiﬁcant reduction in lung PKCα phospho-
rylation in mice 8 hours after sepsis induction. There were
no statistically signiﬁcant diﬀerences in PKCδ and PKCε
phosphorylation between groups (data not shown).
3.4. Eﬀect of SR140333 Treatment on Lung NK Receptor
Expression after Sepsis. mRNA levels of NK receptors, NK-
1R and NK-2R, were analyzed by semiquantitative RT-PCR.
CLP-induced sepsis resulted in a signiﬁcant upregulation
of both the NK receptors in vehicle-treated mice compared
to sham group (Figures 4(a) and 4(b)). NK-1R blocker
had no signiﬁcant eﬀect on the expression of NK-1R and
NK-2R. However, SR140333 treatment 30 minutes before
CLP showed a slight, but nonsigniﬁcant, reduction in the
expression of NK-1R.
3.5. Eﬀect of SR140333 Treatment on SP Levels in Sepsis.
Next, we measured the SP levels in plasma and lung.
Consistent with literature reports, systemic (Figure 5(a))a n d
lung tissue (Figure 5(b)) SP levels were elevated in mice
subjected to CLP surgery. Treatment with SR140333 did not
aﬀect the lung SP levels (Figure 5(b)). However, plasma SP
levels were signiﬁcantly reduced by the NK-1R antagonist,
injected either 30 minutes before or 1 hour after surgery
(Figure 5(a)).
3.6. Eﬀect of GR159897 Treatment on Neutrophil Seques-
tration, Chemokine, and Cytokine Levels in Lung after
CLP Surgery. Lung MPO activity, a measure of neutrophil
inﬁltration, was signiﬁcantly increased in vehicle-treated
animals when compared to the sham mice (Figure 6(a))
8 hours after CLP. However, treatment with the NK-2R
antagonist, GR159897, 1 hour afterCLP, did not signiﬁcantly
reduce the MPO activity in lung (Figure 6(a)). Similarly,
we measured the lung levels of major CXC chemokine,
CXCL-2, and CC chemokine, CCL-2, and cytokines, IL-
1β and IL-6, in lung homogenates. CLP-induced sepsis
resulted in a signiﬁcantly higher CXCL-2 level in vehicle-
treated mice compared to the sham group (Figure 6(b)).
However, GR159897 treatment did not change the elevated
lung CXCL-2 levels observed 8 hours after CLP surgery in
vehicle control group (Figure 6(b)). Further, CCL-2 levels
alsoincreasedsigniﬁcantly8hoursafterCLPsurgerywithout
GR159897 administration compared to that of sham animals
(Figure 6(c)), but this increase in CCL-2 levels was not
aﬀected signiﬁcantly by GR159897 administration 1 hour
after CLP surgery (Figure 6(c)).International Journal of Inﬂammation 5
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Figure 1: Eﬀect of SR140333 administration, either 30 minutes before or 1 hour after CLP, on lung NF-κB DNA-binding activity. Mice (n =
6–9 in each group) were divided into CLP-operated and sham-operated groups. CLP-operated mice received vehicle (DMSO in PBS, 0.25%
v/v) or SR140333 (1mg/kg; 0.25mg/mL) s.c. either 30 minutes before (pretreatment) or 1 hour after (posttreatment) the CLP. Same surgical
procedure as the CLP-operated animals except the cecal ligation and puncture was performed on sham-operated animals. 8 hours after the
CLP procedure, mice were sacriﬁced, and lung (a) NF-κB DNA-binding activity and (b) IκB-α level (representative IκB-α and HPRT control
bands shown on the upper panel) were determined. Results shown are the mean ±S.E.M. “Vehicle + CLP” and “SR140333 + CLP” represent
the groups that received vehicle and SR140333 treatment, respectively, commencing 30 minutes prior to CLP. “CLP + vehicle” and “CLP +
SR140333”representthegroupsthatreceivedvehicleandSR140333treatment,respectively,1hourafterCLP. ∗P<. 001whenvehicle-treated
CLPanimalswerecomparedwithshamgroupanimals; ∗∗P<. 001whenSR140333-treatedCLPanimalswerecomparedwithvehicle-treated
CLP animals; ∞P<. 01 when vehicle-treated CLP animals were compared with sham group animals; / =P<. 05 when SR140333-treated CLP
animals were compared with vehicle-treated CLP animals. CLP: cecal ligation and puncture; HPRT: Hypoxanthine guanine phosphoribosyl
transferase; IOD: integrated optical density.
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Figure 2: Eﬀect of SR140333 administration, either 30 minutes
before or 1 hour after CLP, on lung AP-1 activity. Results shown
are the mean ±S.E.M (n = 8-9 in each group). “Vehicle + CLP” and
“SR140333 + CLP” represent the groups that received vehicle and
SR140333 treatment, respectively, commencing 30 minutes prior
to CLP. “CLP + vehicle” and “CLP + SR140333” represent the
groups that received vehicle and SR140333 treatment, respectively,
1h o u ra f t e rC L P .∗P<. 001 when vehicle-treated CLP animals
were compared with sham group animals; ∗∗P<. 05 when
SR140333-treated CLP animals were compared with vehicle-treated
CLP animals. AP-1: activator protein-1; CLP: cecal ligation and
puncture.
Animals injected only with the vehicle showed a sig-
niﬁcant increase in lung IL-1β (Figure 6(d))a n dI L - 6
(Figure 6(e))l e v e l s8h o u r sa f t e rC L Ps u r g e r yc o m p a r e dt o
that in sham mice. Administration of GR159897 1 hour after
CLP procedure failed to aﬀect the lung IL-1β (Figure 6(d))
and IL-6 (Figure 6(e)) levels compared to the corresponding
levels in the absence of NK-2R antagonist treatment.
4. Discussion
Previously, we have shown that SP acting via NK-1R
was responsible for the leukocyte responses, inﬂammatory
processes, and pulmonary damage in sepsis, and blocking
of NK-1R was beneﬁcial to the mice in managing the
lung injury in polymicrobial sepsis [3]. We observed that
treatment with SR140333, 30 minutes before or 1 hour after
CLP, signiﬁcantly reduced the lung neutrophil inﬁltration
and damage and levels of chemokines, cytokines, and
adhesion molecules 8 hours after CLP [3]. So, our next
goal was to explore the underlying mechanisms for these
beneﬁcial eﬀects of NK-1R antagonism in sepsis. It was
important to see how the downstream intracellular signaling
was propagated and conveyed to the nucleus. We injected6 International Journal of Inﬂammation
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Figure 3: Eﬀect of SR140333 administration, either 30 minutes before or 1 hour after CLP, on lung (a) Phospho ERK1/2 and (b) Phospho-
PKCα.Resultsshownarethemean ±S.E.M(n =6ineachgroup).“Vehicle+CLP”and“SR140333+CLP”representthegroupsthatreceived
vehicle and SR140333 treatment, respectively, commencing 30 minutes prior to CLP. “CLP + vehicle” and “CLP + SR140333” represent the
groups that received vehicle and SR140333 treatment, respectively, 1 hour after CLP. Upper panels show representative western blot gel
pictures of phosphorylated and total ERK1/2 and PKCα for each of the groups. ∗P<. 05 when vehicle-treated CLP animals were compared
with sham group animals; ∗∗P<. 05 when SR140333-treated CLP animals were compared with vehicle-treated CLP animals. CLP: cecal
ligation and puncture; ERK: extracellular signal regulated kinase; IOD: integrated optical density; PKC: protein kinase C.
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Figure 4: Eﬀect of SR140333 administration, either 30 minutes before or 1 hour after CLP, on lung (a) NK-1R and (b) NK-2R mRNA levels.
Results shown are the mean ± S.E.M (n = 6–9 in each group). “Vehicle + CLP” and “SR140333 + CLP” represent the groups that received
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SR140333 either 30 minutes before or 1 hour after CLP, and
the protective eﬀect was analysed 8 hours after CLP.
SP bound to NK-1R is known to upregulate pro-
inﬂammatory cytokines [23]. Activation of inﬂammatory
mediators in sepsis depends mainly on the activation of
transcription factor NF-κB[ 5]. NF-κBi sa c t i v a t e db y
bacterial lipopolysaccharide, cytokines, viral infection, and
lung injury. Furthermore, lung epithelial cells have been
reported to express cytokine genes in response to injury
[24, 25], and NF-κBw a sa c t i v a t e din vitro in these cells by
SP [23]. Consistently, our in vivo data show that treatment of
septic mice with NK-1R antagonist reduced IκBd e g r a d a t i o nInternational Journal of Inﬂammation 7
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Figure 5: Eﬀect of SR140333 administration, either 30 minutes before or 1 hour after CLP, on (a) plasma and (b) lung SP levels. Results
shown are the mean ± S.E.M (n = 6–9 in each group). “Vehicle + CLP” and “SR140333 + CLP” represent the groups that received vehicle
and SR140333 treatment, respectively, commencing 30 minutes prior to CLP. “CLP + vehicle” and “CLP + SR140333” represent the groups
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with sham group animals; ∗∗P<. 05 when SR140333-treated CLP animals were compared with vehicle-treated CLP animals. CLP: cecal
ligation and puncture; SP: substance P.
and nuclear NF-κB activity. Although NF-κB inhibition has
been reported to improve survival in endotoxin models,
the situation is not that straight forward in CLP-induced
sepsis [5]. Impaired survival has been reported when NF-
κB was inhibited by PDTC [26]. While inhibition of NF-
κB decreases the inﬂammatory mediators, complete loss of
antiapoptotic actions of NF-κB might be detrimental in the
host defense [5]. We found a lowering of NF-κB activation,
but the levels were still elevated compared to the basal
levels. In addition, SR140333 treatment in sepsis lowered the
activityofanothertranscriptionfactor,AP-1,whichregulates
various cytokine and chemokine genes [27]. Thus, SR140333
appears to modulate inﬂammatory mediators by regulating
the activation of NF-κB and AP-1.
MAPKs signaling cascade is known to activate NF-κB
[8, 28, 29]. In vitro treatment of Tacr1-expressing cells
with SP increased phosphorylation of ERK1/2 MAPK [23].
In addition, SP-NK-1R-NF-κB pathway upregulates pro-
inﬂammatory cytokines in human colonic epithelial cells
(via PKCδ)[ 30, 31], monocytes (via ERK) [32], murine
macrophagesanddendriticcells(calciumindependent)[33],
human mast cells (via PI3 kinase, PKA) [34], rat peritoneal
mast cells (via MAPKs) [35], human T lymphocytes [36],
human embryonic kidney cells (via PKCδ,E R K )[ 37],
and human mesenteric preadipocytes [38]. We investigated
the potential involvement of ERK in mediating SP-NK-
1R-NF-κB activation in sepsis. ERK phosphorylation was
signiﬁcantly increased in sepsis, implying a role of ERK in
NF-κB activation. However, SR140333 did not reduce ERK
level signiﬁcantly. Tachykinins activate NF-κB by multiple
mechanisms involving phospholipase C, calcium, PKC,
Ras/Raf/ERK, MAPK/ERK kinase, and IκBd e g r a d a t i o n[ 23].
The signaling pathways utilized by SP in cells might vary
with multiple G-protein types, the host cell, and signaling
components [33]. In colonic epithelial cells, SP-induced NF-
κB activation was dependent on PKCδ activity, but not
calcium or ERK [30, 31]. Furthermore, two isoforms of
NK-1R with diﬀerent binding and signaling properties were
identiﬁed recently [32]. Thus, possibly other mechanisms
might be involved in the SP-NK-1R-mediated signaling in
sepsis in addition to ERK.
NK-1R is a GPCR [23, 39], and activation of Gq,
the main G protein associated with NK-1R, is known to
stimulate phospholipase C, release intracellular calcium, and
activate PKC. A PKC inhibitor is shown to block SP-induced
activation of NF-κB in vitro [23]. We observed a signiﬁcant
phosphorylation and activation of PKCα,8h o u r sa f t e r
sepsis, and SR140333 signiﬁcantly reduced lung PKCα levels.
Thus, it is possible to conclude that SP-NK-1R promotes
inﬂammation in polymicrobial sepsis mediated by PKCα.
Expression of NK-1R is reported to be upregulated
by noxious stimuli in inﬂammatory conditions [23, 40,
41]. Increased expression of NK-1R [42] and NK-2R [43]
mRNA has been reported in asthmatic airways. As expected,
expression of NK-1R and NK-2R in our study was elevated
8 hours after CLP-induced sepsis. Treatment with NK-
1R antagonist had no signiﬁcant change in the receptor
expression, although it reduced the lung inﬂammation in
sepsis.
Consistent with our earlier study [2], we observed
elevated lung and plasma SP levels in sepsis in the absence
of SR140333. Although signiﬁcant, compared to sham the
increase was small in magnitude in plasma (more than
1.5 times), but much higher in lungs (more than 3.5
times). Increase in SP levels possibly leads to neurogenic
inﬂammation and pulmonary damage. Blocking the actions
of SP did not aﬀect the lung levels of SP. However, it is
intriguingthatplasmaSPlevelswereloweredbySR140333.It
ispossiblethatblockingofSPactionsresultedinitsincreased
clearancefromthebloodstream,butthelocallevelsatthesite
of injury remained elevated.
SP binds NK-1R with high aﬃnity compared to its
low aﬃnity to the other tachykinin receptors, NK-2R and
NK-3R [44]. NK-2R mRNA, but not NK-3R, has been8 International Journal of Inﬂammation
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Figure 6: Eﬀect of GR159897 administration 1 hour after CLP on lung (a) neutrophil inﬁltration (MPO), (b) CXCL-2, (c) CCL-2, (d) IL-1β
and (e) IL-6 levels. Results shown are the mean ± S.E.M (n = 6–9 in each group). “CLP + vehicle” and “CLP + SR140333” represent the
groups that received vehicle and SR140333 treatment, respectively, 1 hour after CLP. ∗P<. 001 when vehicle-treated CLP animals were
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detected in normal lungs [45]. NK-2R stimulation has been
demonstrated to play a role in bronchoconstriction [46, 47],
and a selective NK-2R inhibitor has been reported to inhibit
bronchoconstriction in asthmatics [48] and to be beneﬁcial
in airway disease [49]. We used GR159897, a selective and
long-acting NK-2R antagonist [18, 19], to further evaluate if
SP mediated its proinﬂammatory activity in sepsis via NK-
2R, in addition to NK-1R. Administration of GR159897 1
hour after CLP failed to reduce MPO levels signiﬁcantly
in septic mice. Also, the chemokines, CCL-2, CXCL-2, and
cytokines, IL-1β and IL-6, were not aﬀected by NK-2R
blocking in sepsis. Tachykinins contract smooth muscles
mainly by interaction with NK-2R, while the vascular and
proinﬂammatory eﬀects are mediated by NK-1R [47]. In the
absence of GR159897, vehicle-treated mice showed signs of
polymicrobial sepsis with elevated MPO activity and lung
chemokine and cytokine levels. Thus, it seems probable that
proinﬂammatory activity of SP in polymicrobial sepsis is
mediated mainly by NK-1R.
In conclusion, the present data reveals the possibility
that SP acting via NK-1R initiates signaling cascade that is
mediated by PKCα and leads to NF-κB and AP-1 activa-
tion and further modulates proinﬂammatory mediators in
polymicrobial sepsis, and the eﬀect of SP is blocked 8 hours
after CLP by NK-1R antagonist SR140333 administered 30
minutes before and 1 hour after CLP. Although earlier work
underlined the importance of SP in lung injury associated
with polymicrobial sepsis, the new information provided
here emphasizes the possible mediators and mechanisms
of the beneﬁcial eﬀects of blocking SP receptors. TheseInternational Journal of Inﬂammation 9
molecular insights move us closer to understanding and
treating sepsis better.
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